Molnupiravir is the world’s first & only oral antiviral to be approved by the US FDA, UK MHRA & Indian CDSCO for treatment of COVID-19 (emergency restricted use). ENTOD Pharmaceuticals (including its subsidiaries and/or associate companies) today announced that it is launching a generic version of Molnupiravir under the brand MOLENTOD™ in India.
The Drugs Controller General of India (DCGI) last week, based on the review of clinical data of molnupiravir, approved molnupiravir for treatment of adult patients with Covid-19, with SpO2 > 93% and who have high risk of progression of the disease including hospitalisation or death.
“Emergency approval of Molnupiravir by DCGI is a very important decision taken by Indian Government and it will help to protect INDIA from the OMICRON wave” said Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals.
ENTOD Pharmaceuticals said that it’s aim is to make the product available as early as possible and that its first batch is already under production. MOLENTOD™ will be available at retail chemists, pharmacy chains, hospitals & online stores across India at an affordable price to patients with an MRP of Rs 649 per strip of 10 capsules, MOLENTOD™ it is very competitively priced against other similar products in the market.
“In the backdrop of steadily rising omicron cases now also in India, the launch of this oral anti-viral drug is another potent addition to India’s arsenal in its fight against the ongoing pandemic. That top global regulatory bodies including our own DGCI have given a go-ahead to this molecule demonstrates the potential efficacy rate of this drug. Also, the short duration nature of this treatment would ensure enhanced compliance helping the country avoid unnecessary hospitalizations or even deaths in the coming months,” said Ms. Anjula Masurkar, Clinical Director, Entod Pharmaceuticals.
The recommended dose of the drug is four capsules (800 mg) twice a day for five days. The duration of treatment of molnupiravir is much shorter compared to other therapies, which is a significant advantage as it reduces the pill burden and enhances compliance. Molnupiravir improves patient compliance for non-hospitalized patients and reduces the chance of hospitalization or death for high-risk populations.
Disclaimer:
Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.About ENTOD Pharmaceuticals Limited (CIN - U24230MH1981PLC025529):
ENTOD Pharmaceuticals is an international research-based pharmaceutical organisation with over three decades of pharmaceutical expertise in Ophthalmology, ENT, Dermatology & other speciality medicine. Globally we have over 200 products in our portfolio, a global field force of over 1000 and highly experienced Quality Assurance, Production and R&D teams. Our products are sold in over 55 countries including the EU, UK, Africa and Asia. Our quality systems are certified in Europe and our manufacturing quality standards adheres to international GMP norms. Our product range includes intracameral injections, eye drops, eye ointments, eye gels and soft gelatin capsules
For further information, please visit www.entodpharma.com & follow us on Twitter@EntodPharma
Advertisements